A phase I safety and feasibility study of Cytori Cell Therapy as a novel thermal burn countermeasure.

Trial Profile

A phase I safety and feasibility study of Cytori Cell Therapy as a novel thermal burn countermeasure.

Recruiting
Phase of Trial: Phase I

Latest Information Update: 09 Nov 2017

At a glance

  • Drugs ECCS 50 (Primary)
  • Indications Burns
  • Focus Adverse reactions
  • Acronyms RELIEF
  • Most Recent Events

    • 09 Nov 2017 According to a Cytori Therapeutics media release, status changed from planning to recruiting.
    • 10 Aug 2017 According to a Cytori Therapeutics media release, enrollment in this trial is expected to begin in Q4 2017.
    • 10 Apr 2017 According to a Cytori Therapeutics media release, the company has that the U.S. Food and Drug Administration (FDA) has approved an Investigational Device Exemption (IDE) for a pilot clinical trial to evaluate Cytori Cell Therapy in patients with thermal burn injury.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top